WO2007056550A2 - Processes for preparation of maytansinol - Google Patents
Processes for preparation of maytansinol Download PDFInfo
- Publication number
- WO2007056550A2 WO2007056550A2 PCT/US2006/043718 US2006043718W WO2007056550A2 WO 2007056550 A2 WO2007056550 A2 WO 2007056550A2 US 2006043718 W US2006043718 W US 2006043718W WO 2007056550 A2 WO2007056550 A2 WO 2007056550A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- maytansinol
- aryl
- protecting group
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Definitions
- the present invention relates to improved processes for the preparation of maytansinol and to an isolated bridged acetal of a C3-ester of maytansinol.
- Maytansinoids are highly cytotoxic drugs.
- the first member of this class, maytansine was isolated by Kupchan et al. from the east African shrub Maytenus serrata and shown to be 100 to 1000 fold more cytotoxic than conventional cancer chemotherapeutic agents like methotrexate, daunorubicin, and vincristine (U.S. Pat. No. 3,896,111).
- maytansinoids such as maytansinol and C-3 esters of maytansinol (U.S. Pat. No. 4,151,042).
- C-3 esters of maytansinol can be classified into two groups: (a) Maytansine and its analogs described above, which are C-3 esters with JV-methyl-L- alanine or derivatives of iV-methyl-L-alanine (U.S. Pat. Nos. 4,137,230; 4,260,608; 5,208,020; and Chem. Pharm. Bull. 12:3441 (1984)); and
- Ansamitocins are a mixture of compounds composed predominantly of ansamitocin P-2, ansamitocin P-3, ansamitocin P-3', ansamitocin P-4 and ansamitocin P-4', Figure 1.
- the ansamitocin P-3 component of ansamitocins typically comprises over 70 % of the total material in ansamitocins. Thus the mixture is often referred to as ansamitocin P-3.
- Ansamitocins are prepared by bacterial fermentation as described in U.S. Patent Nos. 4,162,940, 4,356,265, 4,228,239, and 6,790,954.
- Maytansine, its analogs, and each of the ansamitocin species are C3-esters of maytansinol that can be converted to maytansinol by cleavage of their respective ester side chains. Structures of maytansinols and several C3 esters are shown in Figure 1. Typically, cleavage of the ester moiety is achieved through a reduction reaction.
- C3 -esters of maytansinol can be cleaved by treatment with lithium tri-methoxyaluminum hydride (LATH) or by other alkali alkoxyaluminum hydrides at reduced temperatures, followed by quenching with water or an aqueous salt solution and extraction with organic solvent to give maytansinol, as described in U.S. Patent No. 6,333,410.
- LATH lithium tri-methoxyaluminum hydride
- Maytansinol is the common starting material for the preparation of various maytansinoid drugs, as described in U.S. Patent Nos. 4,322,348, 4,331,598 and 6,333,410.
- the present invention pertains to improved methods to prepare maytansinol by the reduction of C3 -esters of maytansinol.
- the methods result in improved yields of maytansinol by minimizing the formation of undesired side products. Simplified processing also aids in lowering the potential for human exposure to hazardous chemicals.
- a surprising finding leading to this invention is that a major undesired by-product formed during the reduction of C3-esters of maytansinol, such as ansamitocins, with an aluminum-based hydride reducing agent, such as LiAlH 4 or LiAl(OMe) 3 H, is a C3 to C9 bridged acetal of maytansinol.
- the invention describes a process to prepare maytansinol substantially free of bridged acetal from C3 -esters of maytansinol.
- Reduction of C3-esters of maytansinol is carried out as described in U.S. Patent No. 6,333, 410, followed by an aqueous quench, which gives a basic mixture.
- this invention adds an important holding step.
- the holding step comprises maintaining the quenched mixture at a suitable temperature for a suitable period of time to facilitate conversion of any bridged acetal to the desired maytansinol.
- an aqueous base or an aqueous buffer can be added to the quenched mixture to thereby minimize any decomposition of maytansinol and a water immiscible solvent is added to precipitate undesired aluminum- based byproducts of the reducing agent.
- any undesired aluminum-based byproducts can be solubilized by lowering the pH to about 2 or less.
- Another aspect of the invention pertains to the isolation of the bridged acetal and also to methods of converting the isolated bridged acetal to maytansinol under basic or acidic conditions.
- one aspect of the invention is a process for preparing maytansinol comprising: a) reducing a C3 -ester of maytansinol with an aluminum-based hydride reducing reagent; b) quenching the reduction reaction; and c) subjecting the quenched mixture to a holding step; wherein said holding step converts C3 to C9 bridged acetal into maytansinol.
- Another aspect of the invention is an isolated C3 to C9 bridged acetal of a C3-ester of maytansinol.
- a further aspect of the invention is a process for preparing an isolated C3 to C9 bridged acetal of a C3 -ester of maytansinol comprising: a) reducing a C3 -ester of maytansinol with an aluminum-based hydride reducing agent; b) quenching the reduction reaction, to thereby form a C3 to C9 bridged acetal of said C3 -ester of maytansinol; and c) isolating the bridged acetal.
- An even further aspect of the invention provides an isolated C3 to C9 bridged acetal, which is a compound represented by Formula (V):
- X 1 represents H, Cl, or Br
- X 2 represents H, or Me
- X 3 represents H, Me 5 or Me(CH 2 )pCOO, wherein p is between 0-10;
- R 1 represents alkyl, CH(CH 3 )N(CH 3 )Q 5 or CH(CH 3 )N(CH 3 )COR 4 ;
- Q represents H or an amino protecting group;
- R 4 represents alkyl, aryl or (CH 2 ) n (CR 6 R 7 ) m SV, in which n represents 0-9, m represents 0-2, provided m and n are not 0 at the same time, R 6 represents H, alkyl or aryl, R 7 represents H, alkyl or aryl, and V represents H or a thiol protecting group.
- the invention provides a compound represented by Formula (I),
- R 1 represents alkyl, CH(CH 3 )N(CH 3 )Q, or CH(CH 3 )N(CH 3 )COR 4 ;
- Q represents H or an amino protecting group;
- R 4 represents alkyl, aryl or (CH 2 ) n (CR 6 R 7 ) m SV, in which n represents 0-9, m represents 0-2, provided m and n are not 0 at the same time, R 6 represents H, alkyl or aryl, R 7 represents H, alkyl or aryl, and V represents H or a thiol protecting group.
- Figure Ia shows the formula of maytansinol and Figure Ib shows the formulas of the major ansamitocin species that are present in a mixture of ansamitocins isolated from bacterial fermentation.
- Figure 2 shows the formula of maytansine and some of its analogs, and of maytansine analogs bearing the unnatural N-methyl-D-alanine moiety.
- Figure 3 shows the structural formula of the C3 to C9 bridged acetal species produced from reduction of ansamitocin P-3.
- the structural formula of ansamitocin P-3 is also shown for comparison.
- the acetal side chain of the bridged acetal and the ester side chain of ansamitocin P-3 are circled.
- FIG. 4 shows a possible mechanism for the conversion of C3 to C9 bridged acetals of maytansinol to maytansinol.
- the bridged acetal is illustrated by the compound of general formula (I) as described herein.
- C3 -Esters of maytansinol such as ansamitocins, maytansine, and derivatives of maytansine can be reduced by various aluminum-based hydride reducing agents, such as LiAlH 4 or LiAl(OMe) 3 H at low temperature to give maytansinol as described in Figure 2 of U.S. Patent No. 6,333,410. Quenching of these reduction reactions with water or aqueous salts gives a highly basic mixture, i.e., a pH of greater than 11 , that can cause significant decomposition of product if the mixture is allowed to warm.
- various aluminum-based hydride reducing agents such as LiAlH 4 or LiAl(OMe) 3 H at low temperature to give maytansinol as described in Figure 2 of U.S. Patent No. 6,333,410. Quenching of these reduction reactions with water or aqueous salts gives a highly basic mixture, i.e., a pH of greater than 11 , that can cause significant de
- the invention describes a method to reduce C3 -esters of maytansinol followed by a quench and a holding step, which allows any bridged acetal formed in the reduction to be converted to maytansinol.
- the pH of the mixture may be adjusted by addition of acid or aqueous buffer to avoid base induced decomposition of the maytansinol produced and to allow for precipitation of aluminum-based byproducts by adding a water immiscible solvent.
- the starting material for the method of making maytansinol can be any naturally occurring or synthetic C3 -ester of maytansinol and suitable analogues of maytansinol having a modified aromatic ring or modifications at positions other than the C3 position.
- suitable analogues of maytansinol having a modified aromatic ring include:
- C3-ester of maytansinol includes suitable C3-esters of analogues of maytansinol, such as those described above. Any of the analogues described above and any other known analogues of maytansinol can have any of numerous known esters at the C3 position. Thus, one of ordinary skill in the art can readily envision numerous suitable C3-esters of analogues of maytansinol suitable for use as the starting material.
- Non- limiting Examples of C-3 esters of maytansinol include Antibiotic C-15003PND also known as Cl ⁇ -N-des-methyl-ansamitocin, (US patent 4,322,348), 20-demethoxy-20- acyloxymaytansine (US patent 4,294,757), 19-des-cloromaytansine and 20-demethoxy-20- acetoxy-19des-chloromaytansine (US patent 4,294,757).
- the step of reducing a C3 -ester of maytansinol with an aluminum-based hydride reducing agent is well known in the art.
- suitable aluminum-based hydride reducing agents include LiAlH 4 , LiAl(OMe) 3 H, sodium bis(2-methoxyethoxy)aluminum hydride, and other alkali aluminum alkoxy hydrides prepared by addition of a non-stoichiometric amount of alcohol to an alkali aluminum hydride.
- LiAl(OMe) 3 H is preferred.
- the C3 to C9 bridged acetals formed in the reduction reaction can then be converted to maytansinol by allowing the basic quenched mixture to stand during a holding period.
- the holding step comprises maintaining the quenched mixture at a suitable temperature for a suitable period of time to facilitate conversion of any bridged acetal to the desired maytansinol.
- the holding step comprises maintaining the quenched mixture at a temperature of about -15 0 C to about -50 0 C for a period of at least about 0.25 and 5 hours or longer.
- the holding step under the basic conditions allows any bridged acetal formed during the reduction reaction to be converted to maytansinol.
- the time needed for the holding step under the above described conditions will depend on several factors, such as scale of the reaction, concentration, and extract temperatures and can be determined by monitoring the conversion of bridged acetal to maytansinol. For example, a sample aliquot of the reaction is withdrawn and analyzed.
- samples can be prepared and analyzed by several methods, some of which include but are not limited to normal phase high performance liquid chromatography (HPLC) 5 reverse phase HPLC and thin layer chromatography.
- HPLC high performance liquid chromatography
- ansamitocins are reduced with LiAl(OMe) 3 H then quenched with water.
- the bridged acetal can also be converted under acidic conditions. Conversion of the bridged acetal to maytansinol under acidic conditions is not surprising as cleavage of acetal protecting groups is common in organic synthesis. While not wanting to be bound by any explanation, conversion of the bridged acetal to maytansinol by aqueous base is believed to occur by deprotonation of the cyclic carbamate with elimination of aldehyde, Figure 4. [30] Once the bridged acetal is converted to maytansinol, the resulting maytansinol can be isolated by several means known to one skilled in the art.
- the pH of the basic quenched mixture can be adjusted to between about 3 and about 9, most preferably to between about 4 and about 7 by adding an acid or aqueous buffer.
- Suitable acids include hydrochloric acid, phosphoric acid, trifluoroacetic acid, formic acid, and acetic acid. Of these, the preferred acids are formic acid and acetic acid as they give an easily filterable precipitate of aluminum-based byproducts.
- aluminum-based byproducts can be precipitated at the adjusted pH by addition of a water immiscible solvent, such as, for example, ethyl acetate, butyl acetate or dichloromethane.
- the pH can be adjusted and the water immiscible solvent added simultaneously or these steps can be conducted separately and in either order.
- the acid and water immiscible solvent are added at equal to or below 0°C, preferably between - 20°C and -60 0 C, more preferably between -25°C to -50°C, and most preferably between - 30°C and -40°C to precipitate aluminum-based byproducts.
- the precipitated aluminum- based byproducts can be removed by several means known to one skilled in the art. For example the precipitate is easily filtered and the filtrate is found to be substantially free of bridged acetals of the C3 -ester starting material.
- substantially free in this context indicates that less than 10 % by weight of the bridged acetals of the starting C3 -esters remains. More preferably, less than 5 % of the bridged acetals remains, and most preferably less than 2 % of the bridged acetals remains.
- a strong acid such as hydrochloric acid or sulfuric acid can be added after the quench to adjust the pH to about 2 or less to dissolve the aluminum-based byproducts. Dissolving the aluminum-based byproducts allows efficient extraction of the aqueous phase. The amount of acid needed to dissolve the aluminum-based byproducts will depend on the concentration and type of acid used and the determination of these is within the skill of one of ordinary skill in the art. [34] The highly acidic conditions needed to dissolve aluminum based byproducts could potentially decompose a significant portion of the maytansinol. However since the extraction is efficient and solid aluminum-based byproducts are dissolved under the acidic conditions, a rapid extraction can be easily conducted.
- centrifugal extractor for example could . allow the extraction to be conducted while exposing material to highly acidic conditions for only a few minutes or possibly seconds.
- a representative acidic centrifugal extraction has been used in the extraction of penicillin, Podbielniak, W. J., Kaiser, H. R., Ziegenhorn, G. J. (1970) "Centrifugal solvent extraction In the History of Penicillin Production” Chem. Eng. Prog. Symp. Vol. 66 pages 44-50.
- One skilled in the art would know that the extent of decomposition of product under acidic conditions will depend on exposure time and that many methods are available for performing rapid extractions.
- the extracted maytansinol will be substantially free of bridged acetals of the C3-ester starting material.
- a further aspect of the invention is to provide isolated C3 to C9 bridged acetals of maytansinol.
- the bridged acetal is in effect a form of maytansinol that has a protecting group on the C3 and C9 alcohols, so it can be used to prepare synthetic maytansinoid derivatives.
- Any maytansinol analogue, such as those described herein can have any of numerous bridge structures, including those described herein.
- Representative C3-C9 bridged acetals include compounds of Formula (F):
- X 1 represents H, Cl, or Br
- X 2 represents H, or Me
- X 3 represents H, Me, or Me(CH 2 ) p COO, wherein p is between 0-10;
- R 1 represents alkyl, CH(CH 3 )N(CH 3 )Q 5 or CH(CH 3 )N(CH 3 )COR 4 .
- R 1 is alkyl
- the preferred alkyls are C 1 -C 4 alkyl groups, such as CH 3 , CH 2 CH 3 , CH(CHs) 2 , CH 2 CH 2 CH 3 , CH(CH 3 )CH 2 CH 3 , CH 2 CH(CH 3 ) 2 , and (CH 2 ) 3 CH 3 .
- R 1 is CH(CH 3 )N(CH 3 )Q
- Q is H or Q represents an amino protecting group, many of which are described in "Protective groups in organic synthesis" 2 nd Edition.
- Q groups include but are not limited to sulfenamides such as S-alkyl and S- aryl, carbamates such as COO-alkyl, COO-aryl, COOCH 2 CH 2 SiMe 3 , COOCMe 3 , COOCH 2 CCl 3 , and COOCH 2 CF 3 , and silyl groups such as SiMe 3 and SiMe 2 -tBu.
- suitable alkyl groups include, but are not limited to, C 1 -C 10 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, cyclo pentyl and the like.
- suitable aryl groups include, but are not limited to, simple or substituted aryl or heterocyclic with C 1 -C 12 , such as, phenyl, pyridyl, naphthyl, [39]
- R 1 is CH(CH 3 )N(CH 3 )COR 4
- R 4 is selected from alkyl, aryl or (CH 2 ) n (CR 6 R 7 ) ra SV, in which n represents 0-9, m represents 0-2, provided that n and m are not 0 at the same time;
- R 6 represents H, alkyl or aryl,
- R 7 represents H, alkyl or aryl, and V represents H, or a thiol protecting group, many of which are described in "Protective groups in organic synthesis" 2 nd Edition.
- Representative thiol protecting groups include but are not limited to aryl, S-alkyl, S-aryl, SiMe 3 , SiMe 2 -tBu, ArNO 2 , Ar(NO 2 ) 2 , CO-alkyl, CO-aryl, wherein when part of V is an alkyl, suitable alkyl groups include, but are not limited to, linear alkyl, branched alkyl, or cyclic alkyl with C 1 -C 1 Q 1 such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, cyclo pentyl and the like.
- suitable aryl groups include, but are not limited to, simple or substituted aryl or heterocyclic with C 1 -C 12 , such as, phenyl, pyridyl, naphthyl.
- R 1 group present in the acetal side chain can be varied by reducing a C3 -ester of maytansinol that has the corresponding C3 -ester side chain.
- suitable alkyl groups include, but are not limited to, linear C 1 -C 10 alkyl and branched or cyclic C 3 -C 10 alkyl > such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, cyclo pentyl and the like.
- suitable aryl groups include, but are not limited to, simple or substituted C 3 -C 12 aryl or heterocyclic such as, phenyl, pyridyl, and naphthyl.
- suitable alkyl groups include, but are not limited to, linear C 1 -C 10 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, cyclo pentyl and the like.
- suitable aryl groups include, but are not limited to, simple or substituted aryl or heterocyclic with C 3 -C 12 , such as, phenyl, pyridyl, and naphthyl.
- the bridged acetal is represented by Formula (I):
- the bridged acetals can be prepared as byproducts of the reduction of C3 -esters of maytansinol as described above, and can be isolated by chromatography, such as, but not limited to, normal phase chromatography, silica chromatography, cyano-bonded silica chromatography or reverse phase chromatography.
- chromatography such as, but not limited to, normal phase chromatography, silica chromatography, cyano-bonded silica chromatography or reverse phase chromatography.
- isolation is given in Example 3.
- the isolated bridged acetal is converted to maytansinol by incubation with acid or base at a temperature ranging between about 40 0 C to about -40 0 C.
- the reaction is conducted at an ambient temperature.
- the time needed for the reaction will depend on several factors, such as pH, temperature, scale of the reaction, and concentration, and can be monitored by HPLC.
- Suitable acids include hydrochloric acid, phosphoric acid, trifluroacetic acid, acetic acid and formic acid.
- Suitable bases include triethylamine, disopropyl- ethylamine, NaOH or any strong base.
- the pH is adjusted to between about 1 and about 5, optimally to between about 2 and about 4.
- the pH is adjusted to between about 8 and about 13, optimally to between about 9 and about 12.
- a 200 niL three necked flask was equipped with a magnetic stir bar, and a thermometer.
- a I M lithium aluminum hydride solution Of LiAlH 4 in tetrahydrofuran (71 niL, 71 mmol) and 26.8 mL of tetrahydrofuran were transferred to the flask via syringe.
- the flask was cooled in a - 60 0 C bath with stirring until the contents reached -43 0 C.
- a 200 mL three necked flask was equipped with a magnetic stir bar and a thermometer.
- a I M lithium aluminum hydride solution OfLiAlH 4 in tetrahydrofuran (71 niL, 71 mmol) and 28 mL of tetrahydrofuran were transferred to the flask via syringe.
- the flask was cooled in a -60 0 C bath with stirring until the contents reached -43 0 C.
- This example describes conversion of the compound of Formula (I), where R 1 is CH(CH 3 ) 2 , to maytansinol under basic conditions (pH 11) at ambient temperature.
- Diisopropyl ethyl amine was added to a solution of 30 mL tetrahydrofuran and 10 mL deionized water while monitoring the pH using a pH meter until a pH of 11 was obtained.
- the compound of Formula (I) (3.0 mg, mmol) prepared in Example 3 was dissolved in 1.5 mL of pH 11 tetrahydrofuran/water solution at ambient temperature and mixed well. The solution was analyzed by HPLC/MS at various time points. The retention time of the product and the mass spectrum matched that of authentic maytansinol. Conversion was approximately 1 A complete after 15 min.
- Example 5 Conversion of the bridged acetals of Formula (T) to mavtansinol under acidic conditions CpH 2.0 * ) at ambient temperature.
- Trifluoroacetic acid was added to a solution of 30 mL tetrahydrofuran and 10 mL deionized water while monitoring the pH using a pH meter until a pH of 2.0 was obtained.
- the compound of Formula (I) (3.0 mg, mmol) was dissolved in 1.5 mL of the pH 2 tetrahydrofuran/water solution at ambient temperature and mixed well.
- the solution was analyzed by HPLC/MS at various time points. The retention time of the product and the mass spectrum matched that of authentic maytansinol. Conversion was approximately 1 A complete after 1 hour.
- Example 6 An assay for determining the percent conversion of the bridged acetals of
- the organic layer was also analyzed by first diluting with one volume of acetonitrile and analyzing by reverse phase HPLC. Retention times of authentic ansamitocins, maytansinol and the compound of Formula (I) were determined at 16.2 min, 8.7 min, and 16.9 min respectively.
- Example 7 Reduction of ansamitocins with LiAl(OMe) 3 H using water followed by aqueous formic acid quench to give maytansinol.
- Aqueous formic acid (deionized water, 15 mL and 88% formic acid, 1.85 mL) was then added to the flask followed by 66 mL of ethyl acetate. The cooling unit was turned off, and the mixture was allowed to slowly warm to room temperature. The pH of the mixture was checked with pH paper and found to be approximately pH 6. The precipitated aluminum byproducts were removed by vacuum filtration. Solvent was evaporated from the filtrate by rotary evaporation under vacuum.
- Example 8 Reduction of ansamitocins with LiAl(OMeVsHn . followed by aqueous quenching and pH neutralization with formic acid
- Example 9 Reduction of ansamitocins with LiAl(OMe)JH followed by aqueous quenching and acidification with HCl.
- the temperature of the reaction was maintained between -30 0 C and -40 0 C throughout the addition. After addition was complete, the reaction was stirred for 2 hours at between -32 0 C and -37 0 C.
- Deionized water (20 mL) was added dropwise to the -35 0 C reaction to give a basic quenched mixture. After 30 min, aqueous formic acid (deionized water, 40 mL and 88% formic acid, 5.0 mL) was added to the flask, followed by 180 mL of ethyl acetate. The cooling unit was turned off, and the mixture was allowed to slowly warm to room temperature. The pH of the mixture was checked with pH paper and found to be approximately pH 6.
- Example 11 Reduction of D-DM4-SMe to mavtansinol.
- This example describes reduction of D-DM4-SMe, shown in figure 2, to maytansinol.
- D-DM4-SMe (501 mg 5 0.60 mmol) was weighed into a three necked flask equipped with a thermometer. Tetrahydrofuran (2.0 mL) was added to the flask with stirring and the flask was cooled in a -50 0 C cooling bath.
- aqueous formic acid deionized water, 2.0 mL and 88% formic acid, 0.24 mL was added to the flask followed by 9 mL of ethyl acetate.
- the cooling unit was turned off, and the mixture was allowed to slowly warm to room temperature.
- the mixture was vacuum filtered, and solvent was removed by rotary evaporation under vacuum.
- Butyl acetate (2 mL) was added to the residue, the solvent was then evaporated to remove any remaining water.
- the residue was purified by silica chromatography using a mobile phase of dichloromethane:methanol 95:5 (v:v) to give 443 mg of maytansinol (65 % yield by weight).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006311485A AU2006311485B2 (en) | 2005-11-08 | 2006-11-08 | Processes for preparation of maytansinol |
PL06844315T PL1945647T3 (en) | 2005-11-08 | 2006-11-08 | Processes for preparation of maytansinol |
EP06844315A EP1945647B9 (en) | 2005-11-08 | 2006-11-08 | Processes for preparation of maytansinol |
AT06844315T ATE540956T1 (en) | 2005-11-08 | 2006-11-08 | METHOD FOR PRODUCING MAYTANSINOL |
JP2008540200A JP5117390B2 (en) | 2005-11-08 | 2006-11-08 | Preparation method of maytansinol |
ES06844315T ES2380687T3 (en) | 2005-11-08 | 2006-11-08 | Procedures for the preparation of maitansinol |
DK06844315.9T DK1945647T3 (en) | 2005-11-08 | 2006-11-08 | Methods for preparing maytansinol |
CA2625867A CA2625867C (en) | 2005-11-08 | 2006-11-08 | Processes for preparation of maytansinol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73433005P | 2005-11-08 | 2005-11-08 | |
US60/734,330 | 2005-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007056550A2 true WO2007056550A2 (en) | 2007-05-18 |
WO2007056550A3 WO2007056550A3 (en) | 2007-12-06 |
Family
ID=38024003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/043718 WO2007056550A2 (en) | 2005-11-08 | 2006-11-08 | Processes for preparation of maytansinol |
Country Status (10)
Country | Link |
---|---|
US (1) | US7411063B2 (en) |
EP (1) | EP1945647B9 (en) |
JP (1) | JP5117390B2 (en) |
AT (1) | ATE540956T1 (en) |
AU (1) | AU2006311485B2 (en) |
CA (1) | CA2625867C (en) |
DK (1) | DK1945647T3 (en) |
ES (1) | ES2380687T3 (en) |
PL (1) | PL1945647T3 (en) |
WO (1) | WO2007056550A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015009740A2 (en) | 2013-07-15 | 2015-01-22 | Cell Signaling Technology, Inc. | Anti-mucin 1 binding agents and uses thereof |
US11634508B2 (en) | 2019-07-10 | 2023-04-25 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
MX338185B (en) | 2007-01-25 | 2016-04-05 | Dana Farber Cancer Inst Inc | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease. |
WO2008115404A1 (en) | 2007-03-15 | 2008-09-25 | Ludwing Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
EP2188311B1 (en) | 2007-08-14 | 2016-10-05 | Ludwig Institute for Cancer Research Ltd. | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
FR2949469A1 (en) * | 2009-08-25 | 2011-03-04 | Sanofi Aventis | ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
TWI541022B (en) | 2013-12-18 | 2016-07-11 | 應克隆公司 | Compounds to fibroblast growth factor receptor-3 (fgfr3) and methods of treatment |
PT3122757T (en) | 2014-02-28 | 2023-11-03 | Hangzhou Dac Biotech Co Ltd | Charged linkers and their uses for conjugation |
TW201711702A (en) | 2015-06-04 | 2017-04-01 | 應克隆公司 | Therapies utilizing compounds to fibroblast growth factor receptor-3 (FGFR3) |
EP3319936A4 (en) | 2015-07-12 | 2019-02-06 | Suzhou M-conj Biotech Co., Ltd. | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
JP7138350B2 (en) | 2016-11-14 | 2022-09-16 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | Conjugate conjugates, cell-binding molecule-drug conjugates containing the conjugates, and methods of using and producing the conjugates and conjugates |
EP3931198B1 (en) | 2019-03-01 | 2023-04-19 | Celgene Corporation | Preparation of maytansinol |
PT3956332T (en) | 2019-04-18 | 2023-04-24 | Indena Spa | Diasteroselective process for the preparation of thiol- or disulfide-containing maytansinoid esters and intermediates thereof |
JP2022541747A (en) | 2019-07-10 | 2022-09-27 | サイブレクサ 3,インコーポレイテッド | Peptide Conjugates of Microtubule Targeting Agents as Therapeutic Agents |
EP4067497A4 (en) | 2019-11-29 | 2024-03-13 | Microbiopharm Japan Co Ltd | Method for enzymatically producing maytansinol |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5566586A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US20050152913A1 (en) * | 2002-05-13 | 2005-07-14 | Eldridge Ann M. | Process for preapring maytansinol |
-
2006
- 2006-11-08 AT AT06844315T patent/ATE540956T1/en active
- 2006-11-08 WO PCT/US2006/043718 patent/WO2007056550A2/en active Application Filing
- 2006-11-08 US US11/594,156 patent/US7411063B2/en not_active Expired - Fee Related
- 2006-11-08 DK DK06844315.9T patent/DK1945647T3/en active
- 2006-11-08 PL PL06844315T patent/PL1945647T3/en unknown
- 2006-11-08 JP JP2008540200A patent/JP5117390B2/en not_active Expired - Fee Related
- 2006-11-08 EP EP06844315A patent/EP1945647B9/en not_active Not-in-force
- 2006-11-08 ES ES06844315T patent/ES2380687T3/en active Active
- 2006-11-08 AU AU2006311485A patent/AU2006311485B2/en not_active Ceased
- 2006-11-08 CA CA2625867A patent/CA2625867C/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of EP1945647A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015009740A2 (en) | 2013-07-15 | 2015-01-22 | Cell Signaling Technology, Inc. | Anti-mucin 1 binding agents and uses thereof |
EP3699200A1 (en) | 2013-07-15 | 2020-08-26 | Cell Signaling Technology, Inc. | Anti-mucin 1 binding agents and uses thereof |
US11634508B2 (en) | 2019-07-10 | 2023-04-25 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
Also Published As
Publication number | Publication date |
---|---|
ES2380687T3 (en) | 2012-05-17 |
PL1945647T3 (en) | 2012-04-30 |
AU2006311485A1 (en) | 2007-05-18 |
ATE540956T1 (en) | 2012-01-15 |
CA2625867C (en) | 2014-12-23 |
CA2625867A1 (en) | 2007-05-18 |
WO2007056550A3 (en) | 2007-12-06 |
JP2009514978A (en) | 2009-04-09 |
EP1945647A2 (en) | 2008-07-23 |
US7411063B2 (en) | 2008-08-12 |
AU2006311485B2 (en) | 2012-09-27 |
DK1945647T3 (en) | 2012-05-07 |
EP1945647B9 (en) | 2012-11-14 |
JP5117390B2 (en) | 2013-01-16 |
US20070112188A1 (en) | 2007-05-17 |
EP1945647B1 (en) | 2012-01-11 |
EP1945647A4 (en) | 2010-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1945647B9 (en) | Processes for preparation of maytansinol | |
US6277983B1 (en) | Regioselective synthesis of rapamycin derivatives | |
KR100754236B1 (en) | Regioselective synthesis of rapamycin derivatives | |
EP1735321B1 (en) | Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies | |
CA2601670C (en) | Method for the preparation of maytansinoid esters | |
EP2670756B1 (en) | Process for making everolimus | |
EP0507556A1 (en) | Silyl ethers of rapamycin | |
D'Auria et al. | Reidispongiolide A and B, two new potent cytotoxic macrolides from the New Caledonian sponge Reidispongia coerulea | |
CA2564811A1 (en) | Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase | |
SK124199A3 (en) | 12,13-dihydroxy derivatives of tylozine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2625867 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006311485 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006844315 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006311485 Country of ref document: AU Date of ref document: 20061108 Kind code of ref document: A Ref document number: 2008540200 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |